StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.99−0.01 (-0.33%)

Close on Nov 17, 2026Market cap $310.61MP/E –Yield –

Larimar Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Larimar Therapeutics

Larimar Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Larimar Therapeutics figures

See a number that looks wrong?